Poltreg S.A. (WSE:PTG)

Poland flag Poland · Delayed Price · Currency is PLN
24.60
-1.20 (-4.65%)
Mar 2, 2026, 4:08 PM CET
-33.51%
Market Cap 114.72M
Revenue (ttm) n/a
Net Income (ttm) -24.56M
Shares Out 4.66M
EPS (ttm) -5.27
PE Ratio n/a
Forward PE 58.09
Dividend n/a
Ex-Dividend Date n/a
Volume 2,248
Average Volume 4,217
Open 25.20
Previous Close 25.80
Day's Range 24.50 - 25.30
52-Week Range 22.70 - 39.00
Beta 0.74
RSI 46.99
Earnings Date Apr 16, 2026

About Poltreg

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdańsk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 33
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PTG
Full Company Profile

Financial Performance

In 2024, Poltreg's revenue was 350,000, a decrease of -74.98% compared to the previous year's 1.40 million. Losses were -18.71 million, 38.1% more than in 2023.

Financial Statements

News

There is no news available yet.